These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 23201598)

  • 1. Nanoformulation of natural products for prevention and therapy of prostate cancer.
    Sanna V; Siddiqui IA; Sechi M; Mukhtar H
    Cancer Lett; 2013 Jun; 334(1):142-51. PubMed ID: 23201598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of nanotechnology on the delivery of natural products for cancer prevention and therapy.
    Siddiqui IA; Sanna V
    Mol Nutr Food Res; 2016 Jun; 60(6):1330-41. PubMed ID: 26935239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
    Afsharzadeh M; Hashemi M; Babaei M; Abnous K; Ramezani M
    J Cell Physiol; 2020 May; 235(5):4618-4630. PubMed ID: 31674023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer chemoprevention by natural agents: Clinical evidence and potential implications.
    Chhabra G; Singh CK; Ndiaye MA; Fedorowicz S; Molot A; Ahmad N
    Cancer Lett; 2018 May; 422():9-18. PubMed ID: 29471004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy using nanotechnology: focus on cancer.
    Sanna V; Pala N; Sechi M
    Int J Nanomedicine; 2014; 9():467-83. PubMed ID: 24531078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer.
    Flores O; Santra S; Kaittanis C; Bassiouni R; Khaled AS; Khaled AR; Grimm J; Perez JM
    Theranostics; 2017; 7(9):2477-2494. PubMed ID: 28744329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets.
    Fontana F; Raimondi M; Marzagalli M; Di Domizio A; Limonta P
    Cells; 2020 Feb; 9(2):. PubMed ID: 32085497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle therapeutics for prostate cancer treatment.
    Sanna V; Sechi M
    Maturitas; 2012 Sep; 73(1):27-32. PubMed ID: 22341739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural compounds as cancer chemopreventive and chemotherapeutic agents: insights gained from mechanistic and pharmacologic studies.
    Zhu BT
    Anticancer Agents Med Chem; 2012 Dec; 12(10):1157-8. PubMed ID: 22583401
    [No Abstract]   [Full Text] [Related]  

  • 10. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.
    Hrkach J; Von Hoff D; Mukkaram Ali M; Andrianova E; Auer J; Campbell T; De Witt D; Figa M; Figueiredo M; Horhota A; Low S; McDonnell K; Peeke E; Retnarajan B; Sabnis A; Schnipper E; Song JJ; Song YH; Summa J; Tompsett D; Troiano G; Van Geen Hoven T; Wright J; LoRusso P; Kantoff PW; Bander NH; Sweeney C; Farokhzad OC; Langer R; Zale S
    Sci Transl Med; 2012 Apr; 4(128):128ra39. PubMed ID: 22491949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery.
    Gu F; Langer R; Farokhzad OC
    Methods Mol Biol; 2009; 544():589-98. PubMed ID: 19488725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanochemoprevention by bioactive food components: a perspective.
    Siddiqui IA; Mukhtar H
    Pharm Res; 2010 Jun; 27(6):1054-60. PubMed ID: 20221894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
    Kuroda K; Liu H; Kim S; Guo M; Navarro V; Bander NH
    Prostate; 2009 Oct; 69(14):1579-85. PubMed ID: 19575420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticle therapeutics for prostate cancer treatment.
    Sanna V; Sechi M
    Nanomedicine; 2012 Sep; 8 Suppl 1():S31-6. PubMed ID: 22640911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
    Umbricht CA; Benešová M; Schibli R; Müller C
    Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Update of combined therapies with docetaxel for hormone-independent prostate cancer].
    Li TQ; Wang JS
    Zhonghua Nan Ke Xue; 2008 Mar; 14(3):264-7. PubMed ID: 18488345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and dosage of therapeutic nanosuspension for active targeting of docetaxel (WO 2014210485A1).
    Pooja D; Kulhari H; Adams DJ; Sistla R
    Expert Opin Ther Pat; 2016 Jul; 26(7):745-9. PubMed ID: 27088623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A theranostic "SMART" aptamer for targeted therapy of prostate cancer.
    de Franciscis V
    Mol Ther; 2014 Nov; 22(11):1886-8. PubMed ID: 25365986
    [No Abstract]   [Full Text] [Related]  

  • 19. A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.
    Verburg FA; Luster M
    Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1611-1613. PubMed ID: 28677048
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemoprevention of Prostate Cancer by Natural Agents: Evidence from Molecular and Epidemiological Studies.
    Mokbel K; Wazir U; Mokbel K
    Anticancer Res; 2019 Oct; 39(10):5231-5259. PubMed ID: 31570421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.